Mink Historical Balance Sheet

INKT Stock

USD 0.72 0.03 4.35%

Trend analysis of Mink Therapeutics balance sheet accounts such as Other Current Liabilities of 8.5 M or Total Current Liabilities of 13.7 M provides information on Mink Therapeutics' total assets, liabilities, and equity, which is the actual value of Mink Therapeutics to its prevalent stockholders. By breaking down trends over time using Mink Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Mink Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Mink Therapeutics is a good buy for the upcoming year.

Mink Therapeutics Inventory

1,505.66

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Mink Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For more information on how to buy Mink Stock please use our How to Invest in Mink Therapeutics guide.

About Mink Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Mink Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Mink Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Mink Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Mink currently owns. An asset can also be divided into two categories, current and non-current.

Mink Therapeutics Balance Sheet Chart

At this time, Mink Therapeutics' Other Current Liabilities is comparatively stable compared to the past year. Total Current Liabilities is likely to gain to about 13.7 M in 2024, whereas Net Tangible Assets are likely to drop (484.6 K) in 2024.

Short Long Term Debt Total Total Current Liabilities Other Liab Net Tangible Assets

Total Current Liabilities

Total Current Liabilities is an item on Mink Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Mink Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Most accounts from Mink Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Mink Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Mink Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For more information on how to buy Mink Stock please use our How to Invest in Mink Therapeutics guide.At this time, Mink Therapeutics' Other Current Liabilities is comparatively stable compared to the past year. Total Current Liabilities is likely to gain to about 13.7 M in 2024, whereas Net Tangible Assets are likely to drop (484.6 K) in 2024.

	2023	2024 (projected)
Short and Long Term Debt Total	50.4M	38.8M
Total Assets	4.6M	4.3M

Short Long Term Debt Total Total Assets

Mink Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets
Total Assets		0.59	0.73	0.76	0.91	-0.61	0.79	0.48	0.05	-0.87	-0.45	0.45	1.0	0.48	0.59	1.0	-0.61	0.1	-0.75	-0.14	0.47	0.72	-0.64	0.91	0.44	1.0
Short Long Term Debt Total	0.59		0.91	0.88	0.57	-0.97	0.67	0.83	-0.44	-0.67	-0.86	0.75	0.58	0.83	1.0	0.58	-0.97	0.47	-0.61	0.21	0.61	0.86	-0.43	0.23	0.86	0.57
Other Current Liab	0.73	0.91		0.99	0.62	-0.95	0.68	0.63	-0.4	-0.69	-0.73	0.59	0.72	0.63	0.91	0.72	-0.95	0.47	-0.57	0.3	0.71	0.76	-0.38	0.46	0.65	0.72
Total Current Liabilities	0.76	0.88	0.99		0.65	-0.95	0.7	0.64	-0.4	-0.72	-0.73	0.63	0.75	0.64	0.88	0.75	-0.95	0.5	-0.59	0.27	0.71	0.76	-0.4	0.49	0.64	0.75
Total Stockholder Equity	0.91	0.57	0.62	0.65		-0.59	0.96	0.64	-0.2	-0.99	-0.63	0.54	0.91	0.64	0.57	0.91	-0.59	0.33	-0.95	-0.49	0.14	0.86	-0.9	0.74	0.61	0.9
Other Liab	-0.61	-0.97	-0.95	-0.95	-0.59		-0.69	-0.81	0.53	0.69	0.87	-0.78	-0.6	-0.81	-0.97	-0.6	1.0	-0.59	0.61	-0.23	-0.64	-0.84	0.43	-0.26	-0.83	-0.6
Net Tangible Assets	0.79	0.67	0.68	0.7	0.96	-0.69		0.75	-0.47	-0.98	-0.8	0.61	0.8	0.75	0.67	0.8	-0.69	0.56	-0.98	-0.49	0.07	0.93	-0.93	0.53	0.75	0.78
Property Plant And Equipment Net	0.48	0.83	0.63	0.64	0.64	-0.81	0.75		-0.52	-0.75	-0.94	0.95	0.47	1.0	0.83	0.47	-0.81	0.58	-0.77	-0.21	0.26	0.92	-0.68	0.08	0.99	0.46
Current Deferred Revenue	0.05	-0.44	-0.4	-0.4	-0.2	0.53	-0.47	-0.52		0.34	0.75	-0.41	0.05	-0.52	-0.44	0.05	0.53	-0.97	0.41	0.19	0.16	-0.49	0.4	0.39	-0.56	0.07
Net Debt	-0.87	-0.67	-0.69	-0.72	-0.99	0.69	-0.98	-0.75	0.34		0.75	-0.65	-0.87	-0.75	-0.67	-0.87	0.69	-0.45	0.97	0.45	-0.17	-0.93	0.91	-0.63	-0.73	-0.86
Retained Earnings	-0.45	-0.86	-0.73	-0.73	-0.63	0.87	-0.8	-0.94	0.75	0.75		-0.83	-0.44	-0.94	-0.86	-0.44	0.87	-0.78	0.78	0.19	-0.21	-0.92	0.68	-0.03	-0.96	-0.43
Accounts Payable	0.45	0.75	0.59	0.63	0.54	-0.78	0.61	0.95	-0.41	-0.65	-0.83		0.44	0.95	0.75	0.44	-0.78	0.52	-0.63	-0.08	0.4	0.8	-0.52	0.09	0.89	0.44
Cash	1.0	0.58	0.72	0.75	0.91	-0.6	0.8	0.47	0.05	-0.87	-0.44	0.44		0.47	0.58	1.0	-0.6	0.1	-0.76	-0.16	0.45	0.71	-0.65	0.91	0.44	1.0
Non Current Assets Total	0.48	0.83	0.63	0.64	0.64	-0.81	0.75	1.0	-0.52	-0.75	-0.94	0.95	0.47		0.83	0.47	-0.81	0.58	-0.77	-0.21	0.26	0.92	-0.68	0.08	0.99	0.46
Long Term Debt	0.59	1.0	0.91	0.88	0.57	-0.97	0.67	0.83	-0.44	-0.67	-0.86	0.75	0.58	0.83		0.58	-0.97	0.47	-0.61	0.21	0.61	0.86	-0.43	0.23	0.86	0.57
Cash And Short Term Investments	1.0	0.58	0.72	0.75	0.91	-0.6	0.8	0.47	0.05	-0.87	-0.44	0.44	1.0	0.47	0.58		-0.6	0.1	-0.76	-0.16	0.45	0.71	-0.65	0.91	0.44	1.0
Net Receivables	-0.61	-0.97	-0.95	-0.95	-0.59	1.0	-0.69	-0.81	0.53	0.69	0.87	-0.78	-0.6	-0.81	-0.97	-0.6		-0.59	0.61	-0.23	-0.65	-0.84	0.43	-0.26	-0.82	-0.6
Common Stock Shares Outstanding	0.1	0.47	0.47	0.5	0.33	-0.59	0.56	0.58	-0.97	-0.45	-0.78	0.52	0.1	0.58	0.47	0.1	-0.59		-0.49	-0.21	-0.07	0.55	-0.48	-0.24	0.59	0.08
Non Current Liabilities Total	-0.75	-0.61	-0.57	-0.59	-0.95	0.61	-0.98	-0.77	0.41	0.97	0.78	-0.63	-0.76	-0.77	-0.61	-0.76	0.61	-0.49		0.6	0.02	-0.93	0.97	-0.49	-0.77	-0.74
Inventory	-0.14	0.21	0.3	0.27	-0.49	-0.23	-0.49	-0.21	0.19	0.45	0.19	-0.08	-0.16	-0.21	0.21	-0.16	-0.23	-0.21	0.6		0.78	-0.3	0.76	-0.11	-0.19	-0.13
Other Current Assets	0.47	0.61	0.71	0.71	0.14	-0.64	0.07	0.26	0.16	-0.17	-0.21	0.4	0.45	0.26	0.61	0.45	-0.65	-0.07	0.02	0.78		0.25	0.24	0.38	0.24	0.47
Other Stockholder Equity	0.72	0.86	0.76	0.76	0.86	-0.84	0.93	0.92	-0.49	-0.93	-0.92	0.8	0.71	0.92	0.86	0.71	-0.84	0.55	-0.93	-0.3	0.25		-0.83	0.37	0.93	0.7
Total Liab	-0.64	-0.43	-0.38	-0.4	-0.9	0.43	-0.93	-0.68	0.4	0.91	0.68	-0.52	-0.65	-0.68	-0.43	-0.65	0.43	-0.48	0.97	0.76	0.24	-0.83		-0.42	-0.67	-0.63
Net Invested Capital	0.91	0.23	0.46	0.49	0.74	-0.26	0.53	0.08	0.39	-0.63	-0.03	0.09	0.91	0.08	0.23	0.91	-0.26	-0.24	-0.49	-0.11	0.38	0.37	-0.42		0.04	0.91
Property Plant And Equipment Gross	0.44	0.86	0.65	0.64	0.61	-0.83	0.75	0.99	-0.56	-0.73	-0.96	0.89	0.44	0.99	0.86	0.44	-0.82	0.59	-0.77	-0.19	0.24	0.93	-0.67	0.04		0.43
Total Current Assets	1.0	0.57	0.72	0.75	0.9	-0.6	0.78	0.46	0.07	-0.86	-0.43	0.44	1.0	0.46	0.57	1.0	-0.6	0.08	-0.74	-0.13	0.47	0.7	-0.63	0.91	0.43

Click cells to compare fundamentals

Mink Therapeutics Account Relationship Matchups

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Mink Stock Analysis

When running Mink Therapeutics' price analysis, check to measure Mink Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mink Therapeutics is operating at the current time. Most of Mink Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mink Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mink Therapeutics' price. Additionally, you may evaluate how the addition of Mink Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Mink Historical Balance Sheet

Mink Therapeutics Inventory

1,505.66

About Mink Balance Sheet Analysis

Mink Therapeutics Balance Sheet Chart

Total Current Liabilities

Net Tangible Assets

Mink Therapeutics balance sheet Correlations

Mink Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Mink Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Long Term Debt	+ 1.0	Short Long Term Debt Total
Net Receivables	+ 1.0	Other Liab
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net

Net Debt	- 0.99	Total Stockholder Equity
Non Current Liabilities Total	- 0.98	Net Tangible Assets
Net Debt	- 0.98	Net Tangible Assets
Net Receivables	- 0.97	Long Term Debt
Common Stock Shares Outstanding	- 0.97	Current Deferred Revenue
Long Term Debt	- 0.97	Other Liab